{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:22Z","timestamp":1788307222880,"version":"build-2803163510"},"reference-count":15,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>In the United States, children receive 2 doses of measles-mumps-rubella vaccine (MMR) and varicella vaccine (V), the first between ages 1 to 2 years and the second between ages 4 to 6 years. Among 1- to 2-year-olds, the risk of febrile seizures 7 to 10 days after MMRV is double that after separate MMR + V. Whether MMRV or MMR + V affects risk for febrile seizure risk among 4- to 6-year-olds has not been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Among 4- to 6-year-old Vaccine Safety Datalink members, we identified seizures in the emergency department and hospital from 2000 to 2008 and outpatient visits for fever from 2006 to 2008 during days 7 to 10 and 0 to 42 after MMRV and MMR + V. Incorporating medical record reviews, we assessed seizure risk after MMRV and MMR + V.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>From 2006 through 2008, 86\u2009750 children received MMRV; from 2000 through 2008, 67\u2009438 received same-day MMR + V. Seizures were rare throughout days 0 to 42 without peaking during days 7 to 10. There was 1 febrile seizure 7 to 10 days after MMRV and 0 after MMR + V. Febrile seizure risk was 1 per 86\u2009750 MMRV doses (95% confidence interval, 1 per 3\u2009426\u2009441, 1 per 15\u2009570) and 0 per 67\u2009438 MMR + V doses (1 per 18\u2009282).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>This study provides reassurance that MMRV and MMR + V were not associated with increased risk of febrile seizures among 4- to 6-year-olds. We can rule out with 95% confidence a risk greater than 1 febrile seizure per 15\u2009500 MMRV doses and 1 per 18\u2009000 MMR + V doses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1542\/peds.2011-3198","type":"journal-article","created":{"date-parts":[[2012,4,2]],"date-time":"2012-04-02T20:20:28Z","timestamp":1333398028000},"page":"809-814","source":"Crossref","is-referenced-by-count":46,"title":["Measles-Containing Vaccines and Febrile Seizures in Children Age 4 to 6 Years"],"prefix":"10.1542","volume":"129","author":[{"given":"Nicola P.","family":"Klein","sequence":"first","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Lewis","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Baxter","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Weintraub","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Glanz","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Colorado, Denver, Colorado and Department of Epidemiology, Colorado School of Public Health, Aurora, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Naleway","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northwest, Portland, Oregon;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Group Health Research Institute, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nordin","sequence":"additional","affiliation":[{"name":"HealthPartners Research Foundation, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Lieu","sequence":"additional","affiliation":[{"name":"Center for Child Health Care Studies, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, and Division of General Pediatrics, Children\u2019s Hospital Boston, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Belongia","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Research Foundation, Marshfield, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Fireman","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2012,5,1]]},"reference":[{"key":"2022051611125047200_B1","first-page":"1","article-title":"Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine.","volume-title":"Pediatr Infect Dis J","author":"Belongia","year":"2010"},{"issue":"10","key":"2022051611125047200_B2","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/MLR.0b013e3180616c0a","article-title":"Real-time vaccine safety surveillance for the early detection of adverse events.","volume":"45","author":"Lieu","year":"2007","journal-title":"Med Care"},{"issue":"32","key":"2022051611125047200_B3","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1016\/j.vaccine.2009.05.036","article-title":"An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink.","volume":"27","author":"Yih","year":"2009","journal-title":"Vaccine"},{"issue":"10","key":"2022051611125047200_B4","first-page":"258","article-title":"Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine.","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"2022051611125047200_B5","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1542\/peds.2006-0678","article-title":"Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.","volume":"118","author":"LeBaron","year":"2006","journal-title":"Pediatrics"},{"issue":"1","key":"2022051611125047200_B6","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-0665","article-title":"Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics"},{"issue":"34","key":"2022051611125047200_B7","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1016\/j.vaccine.2009.05.056","article-title":"Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.","volume":"27","author":"Jacobsen","year":"2009","journal-title":"Vaccine"},{"key":"2022051611125047200_B8","first-page":"1","article-title":"Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"59","author":"Marin","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"2022051611125047200_B9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1542\/peds.100.5.767","article-title":"MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project.","volume":"100","author":"Davis","year":"1997","journal-title":"Pediatrics"},{"issue":"3","key":"2022051611125047200_B10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.vaccine.2008.10.064","article-title":"Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.","volume":"27","author":"Gillet","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"2022051611125047200_B11","first-page":"91","article-title":"Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran.","volume":"14","author":"Esteghamati","year":"2011","journal-title":"Arch Iran Med"},{"issue":"6","key":"2022051611125047200_B12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1017\/S0317167100008246","article-title":"Febrile seizures: current views and investigations.","volume":"36","author":"Reid","year":"2009","journal-title":"Can J Neurol Sci"},{"issue":"2","key":"2022051611125047200_B13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1542\/peds.2005-0092","article-title":"A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.","volume":"117","author":"Reisinger","year":"2006","journal-title":"Pediatrics"},{"issue":"2","key":"2022051611125047200_B14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.inf.0000250689.09396.21","article-title":"Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.","volume":"26","author":"Vesikari","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"20","key":"2022051611125047200_B15","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.vaccine.2009.02.044","article-title":"Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.","volume":"27","author":"Halperin","year":"2009","journal-title":"Vaccine"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/129\/5\/809\/896690\/peds_2011-3198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/129\/5\/809\/896690\/peds_2011-3198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T07:13:14Z","timestamp":1652685194000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/129\/5\/809\/73854\/Measles-Containing-Vaccines-and-Febrile-Seizures"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,1]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,5,1]]},"published-print":{"date-parts":[[2012,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2011-3198","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,1]]}}}